Compare iShares MSCI ACWI ETF (ACWI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares MSCI ACWI ETF trades at $155.58, while Zimmer Biomet Holdings Inc trades at $88.44 (market cap $17.30B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while iShares MSCI ACWI ETF pays none, and iShares MSCI ACWI ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ACWI | ZBH | |
|---|---|---|
52-Week High | $159.97 | $107.71 |
52-Week Low | $128.32 | $79.58 |
Market Cap | — | $17.30B |
Sector | — | Health |
Enterprise Value | — | $24.34B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $157.97, up 1.17% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and positive news flow, with a dividend scheduled for June 2026. Key support lies at $156, while resistance is at $159.
Outlook remains positive due to robust EPS growth and investor inflows into global equity ETFs. Risks include overbought technical conditions and market volatility. The stock's valuation and momentum support a constructive view for long-term investors.
Zimmer Biomet (ZBH) trades at $89.41, up 2.22% with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with 70% gross margins and revenue growth to $8.23B in 2025, though net margins compressed to 8.56%. Recent developments include a $140M acquisition and plans to hire 500 tech employees in India, supporting growth initiatives. Valuation metrics appear reasonable with P/E of 23.25 and P/S of 2.11.
ZBH offers moderate upside to the $98.33 consensus target with analyst sentiment mixed (43% buy, 50% hold). Key risks include rising debt levels (debt-to-asset ratio increased to 32.57% in 2025) and margin pressure. The company's $1B share repurchase program and dividend provide shareholder returns, but execution on growth initiatives remains critical for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
